Development of hepatic central lobular necrosis secondary to acetaminophen overdose can be prevented effectively by which of the following?
Which of the following drugs is NOT known to contribute to urinary incontinence?
Which of the following drug classes can be used for the treatment of premature ejaculation?
Which of the following statements is NOT true regarding Trientine?
Obstructive jaundice may be seen as a side effect of therapy with which of the following medications?
Which of the following drugs has been withdrawn from the market?
Fomepizole is the antidote for which type of poisoning?
Pralidoxime is not useful in poisoning with:
What is the best indicator for the beneficial effect of atropine in a patient with organophosphorous poisoning?
Which of the following medications is associated with hyperkalemia?
Explanation: **Explanation:** Acetaminophen (Paracetamol) toxicity occurs when its toxic metabolite, **NAPQI** (N-acetyl-p-benzoquinone imine), exhausts the liver's glutathione stores. Once glutathione is depleted, NAPQI binds to hepatocytes, causing **centrilobular necrosis**. **Why Methionine is correct:** Methionine is a precursor for the synthesis of **glutathione**. By increasing the bioavailability of glutathione, it facilitates the detoxification of NAPQI. While **N-acetylcysteine (NAC)** is the preferred antidote in clinical practice due to better tolerance, Methionine is an effective alternative if administered within 8–10 hours of ingestion. **Analysis of Incorrect Options:** * **Dimercaprol (BAL):** A chelating agent used primarily for heavy metal poisoning (Arsenic, Mercury, and Lead). It has no role in acetaminophen metabolism. * **Sodium nitrite & Amyl nitrite:** These are components of the "Cyanide Antidote Kit." They work by converting hemoglobin to methemoglobin, which has a high affinity for cyanide, preventing it from binding to cytochrome oxidase. **NEET-PG High-Yield Pearls:** 1. **Antidote of Choice:** N-acetylcysteine (NAC) is the drug of choice for paracetamol overdose. It acts as a glutathione substitute and precursor. 2. **Toxic Metabolite:** NAPQI is produced via the **CYP2E1** pathway. 3. **Rumack-Matthew Nomogram:** Used to predict hepatotoxicity based on plasma paracetamol levels vs. time since ingestion. 4. **Clinical Sign:** Centrilobular necrosis (Zone 3) is characteristic because this area has the highest concentration of CYP450 enzymes.
Explanation: **Explanation:** Urinary incontinence is a common drug-induced side effect that occurs through various mechanisms affecting the detrusor muscle or the internal urethral sphincter. **Why Metoprolol is the correct answer:** Metoprolol is a **cardioselective $\beta_1$-blocker**. The urinary bladder's physiology is primarily governed by $\beta_3$ receptors (relaxation of detrusor) and $\alpha_1$ receptors (contraction of the internal sphincter). Since Metoprolol does not significantly interact with $\alpha$ receptors or $\beta_3$ receptors, it does not typically contribute to urinary incontinence. **Analysis of Incorrect Options:** * **Nicardipine (Calcium Channel Blocker):** CCBs reduce calcium influx into smooth muscles, leading to **detrusor underactivity**. This can cause urinary retention followed by **overflow incontinence**. * **Haloperidol (Antipsychotic):** First-generation antipsychotics have significant dopamine-blocking and anticholinergic properties. However, they also cause **$\alpha$-adrenergic blockade**, which relaxes the internal urethral sphincter, leading to **stress incontinence**. * **Prazosin ($\alpha_1$-blocker):** This is a classic cause of drug-induced **stress incontinence**. By blocking $\alpha_1$ receptors at the bladder neck and proximal urethra, it decreases urethral resistance, making it difficult to retain urine, especially during coughing or sneezing. **NEET-PG High-Yield Pearls:** 1. **$\alpha_1$-Agonists** (e.g., Pseudoephedrine) cause urinary retention. 2. **$\alpha_1$-Antagonists** (e.g., Prazosin) cause stress incontinence. 3. **Diuretics** (e.g., Furosemide) cause "functional" incontinence due to polyuria and urgency. 4. **Cholinesterase inhibitors** (e.g., Donepezil) can cause urge incontinence by increasing detrusor activity.
Explanation: **Selective Serotonin Reuptake Inhibitors (SSRIs)** are the first-line pharmacological treatment for premature ejaculation (PE) [1]. The underlying mechanism involves the modulation of the ejaculatory reflex. Serotonin (5-HT) acts as an inhibitory neurotransmitter in the central nervous system; by blocking its reuptake, SSRIs increase intrasynaptic serotonin levels, which stimulates 5-HT2C receptors and leads to a delay in ejaculation. **Dapoxetine** is a short-acting SSRI specifically designed and FDA-approved for "on-demand" treatment of PE due to its rapid onset and short half-life. **Analysis of Incorrect Options:** * **Nitric Oxide Inhibitors:** These would theoretically cause vasoconstriction and impair erectile function, rather than delaying ejaculation. * **SNRIs:** While some SNRIs (like Venlafaxine) may delay ejaculation as a side effect [3], they are not the primary class used for this indication and lack the specific clinical evidence compared to SSRIs. * **PDE Inhibitors (e.g., Sildenafil):** These are the gold standard for **Erectile Dysfunction (ED)**. While they may be used as an adjunct if PE is secondary to ED, they do not directly modulate the ejaculatory threshold. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice (on-demand):** Dapoxetine (Shortest acting SSRI). * **Off-label daily use:** Paroxetine, Sertraline, or Fluoxetine [1]. * **Other treatments:** Topical lignocaine-prilocaine spray (decreases penile sensitivity) and Clomipramine (a TCA with strong serotonergic activity) [1]. * **Side effect profile:** Be mindful of "SSRI discontinuation syndrome" and sexual dysfunction (decreased libido) with chronic use [2].
Explanation: ### Explanation **1. Why Option A is the Correct Answer (The False Statement):** The statement is incorrect because it misrepresents the relative potency and clinical hierarchy of these drugs. **Penicillamine** is actually the **first-line** and **more potent** copper-chelating agent for Wilson’s disease. **Trientine** (triethylene tetramine) is considered a **second-line** alternative, primarily reserved for patients who are intolerant to Penicillamine (e.g., those developing severe hypersensitivity or nephrotoxicity). Therefore, Trientine is the alternative to Penicillamine, not the other way around. **2. Analysis of Incorrect Options (True Statements):** * **Option B:** Trientine is indeed **orally effective** but has a relatively **short duration of action**, necessitating multiple daily doses (usually 2–4 times a day). * **Option C:** Trientine is a non-selective chelator. While it targets copper, it can also chelate iron, potentially leading to **iron deficiency** with chronic use. * **Option D:** Because Trientine chelates divalent cations, co-administration with iron supplements leads to the formation of non-absorbable complexes. To prevent this, a **2-hour gap** is mandatory between the ingestion of Trientine and iron. **Clinical Pearls for NEET-PG:** * **Wilson’s Disease Treatment Hierarchy:** 1. **Penicillamine:** Most potent, first-line (Side effects: Nephrotic syndrome, Myasthenia gravis, Elastosis perforans serpiginosa). 2. **Trientine:** Second-line (Less toxic than Penicillamine). 3. **Zinc:** Used for maintenance or in asymptomatic patients (prevents copper absorption by inducing Metallothionein). * **Mechanism:** Trientine promotes the cupriuretic effect (urinary excretion of copper). * **Pregnancy:** Trientine is generally considered safer than Penicillamine during pregnancy for managing Wilson's disease.
Explanation: **Explanation:** The correct answer is **Chlorpromazine**. **Mechanism of Toxicity:** Chlorpromazine, a typical antipsychotic of the phenothiazine class, is a classic cause of **intrahepatic cholestatic jaundice**. This is an idiosyncratic (Type B) hypersensitivity reaction rather than a dose-dependent effect. It typically occurs within the first 1–4 weeks of therapy. The drug causes interference with bile canalicular transport and leads to the inflammation of the portal tracts, resulting in "obstructive" features (elevated alkaline phosphatase and conjugated bilirubin) despite no physical blockage in the large bile ducts. **Analysis of Incorrect Options:** * **A. Isoniazid:** While highly hepatotoxic, Isoniazid typically causes **hepatocellular necrosis** (elevated ALT/AST) rather than obstructive jaundice. Its toxicity is mediated by its metabolite, acetylhydrazine. * **B. Reserpine:** This older antihypertensive/antipsychotic is associated with side effects like depression, parkinsonism, and gastric ulcers, but it is not known for causing cholestatic jaundice. * **C. Furosemide:** This loop diuretic is primarily associated with ototoxicity, hypokalemia, and hyperuricemia. It does not have a significant association with obstructive jaundice. **High-Yield Clinical Pearls for NEET-PG:** * **Cholestatic Jaundice Triad:** Other drugs frequently causing this pattern include **Erythromycin estolate**, **Oral Contraceptive Pills (OCPs)**, and **Anabolic Steroids**. * **Chlorpromazine Side Effects:** Remember the "3 Cs" – **C**holestatic jaundice, **C**orneal deposits, and **C**onvulsions (lowers seizure threshold). * **Management:** The jaundice is usually reversible upon discontinuation of the drug.
Explanation: **Explanation:** **Correct Option: D. Rofecoxib** Rofecoxib is a selective **COX-2 inhibitor** (NSAID) that was voluntarily withdrawn from the global market in 2004. The withdrawal was based on data from the APPROVe trial, which demonstrated a significantly increased risk of **cardiovascular events**, specifically myocardial infarction and stroke. The underlying mechanism involves the inhibition of prostacyclin (PGI2) in the vascular endothelium without affecting thromboxane A2 (TXA2) in platelets. This creates a **pro-thrombotic state**, leading to increased clotting risks. Other "coxibs" like Valdecoxib were also withdrawn, while Celecoxib remains on the market with a black-box warning. **Incorrect Options:** * **A. Nicorandil:** A potassium channel opener and nitric oxide donor used in the management of stable angina. It remains in clinical use. * **B. Ropinirole:** A non-ergot dopamine agonist (D2/D3 selective) used in the treatment of Parkinson’s disease and Restless Legs Syndrome. * **C. Rotigotine:** A dopamine agonist delivered via a transdermal patch for Parkinson’s disease. It is currently available and used. **High-Yield Clinical Pearls for NEET-PG:** * **Banned NSAIDs:** Apart from Rofecoxib and Valdecoxib, **Lumiracoxib** was withdrawn due to hepatotoxicity. * **Gastro-sparing:** Selective COX-2 inhibitors have a lower risk of peptic ulcers compared to non-selective NSAIDs (like Aspirin or Naproxen) but carry higher CV risks. * **Drug of Choice:** Ropinirole and Pramipexole are preferred over ergot derivatives (like Bromocriptine) in Parkinson's to avoid pulmonary/cardiac fibrosis.
Explanation: **Explanation:** **Correct Answer: C. Ethylene glycol poisoning** Fomepizole is a potent competitive inhibitor of the enzyme **Alcohol Dehydrogenase (ADH)**. In cases of ethylene glycol or methanol poisoning, the toxicity is not caused by the parent alcohols themselves, but by their toxic metabolites (glycolic/oxalic acid and formic acid, respectively). By inhibiting ADH, Fomepizole prevents the conversion of ethylene glycol into these toxic metabolites, allowing the parent compound to be excreted harmlessly by the kidneys. It is preferred over ethanol because it does not cause CNS depression or hypoglycemia. **Analysis of Incorrect Options:** * **A. Mushroom poisoning:** The antidote depends on the toxin. For *Amanita phalloides* (containing amatoxins), **Silibinin** or N-acetylcysteine is used. For muscarinic symptoms, **Atropine** is the drug of choice. * **B. Benzodiazepine poisoning:** The specific competitive antagonist for benzodiazepine receptors is **Flumazenil**. * **D. Organophosphorus poisoning:** Treatment involves **Atropine** (to reverse muscarinic effects) and **Pralidoxime/Oximes** (to reactivate the acetylcholinesterase enzyme). **High-Yield Clinical Pearls for NEET-PG:** * **Mnemonic:** **F**omepizole **F**orgets the **F**uel (Ethylene glycol/Methanol). * **Methanol Toxicity:** Presents with a "snowfield" vision (retinal toxicity) and metabolic acidosis. * **Ethylene Glycol Toxicity:** Characterized by **calcium oxalate crystals** (envelope-shaped) in urine and acute renal failure. * **Indications for Hemodialysis:** If Fomepizole is unavailable or if there is severe metabolic acidosis/end-organ damage.
Explanation: **Explanation:** The core concept behind this question is the mechanism of action of **Cholinesterase Reactivators** (Oximes) and the chemical nature of different anticholinesterases. **Why Edrophonium is the correct answer:** Pralidoxime (2-PAM) works by displacing the phosphate group from the "phosphorylated" acetylcholinesterase (AChE) enzyme, thereby regenerating it. This is only effective against **Irreversible Organophosphates**. Edrophonium is a **reversible, short-acting carbamate** (non-organophosphate) that binds only to the anionic site of the enzyme via ionic bonds. Since there is no covalent "phosphorylation" of the enzyme, there is no role for an oxime to "reactivate" it. Furthermore, oximes themselves have weak anticholinesterase activity and can potentially worsen a carbamate overdose. **Analysis of incorrect options:** * **Malathion & Parathion (Options B & C):** These are classic **Organophosphate** insecticides. They cause irreversible inhibition of AChE by phosphorylating the esteratic site. Pralidoxime is specifically indicated here to "de-phosphorylate" the enzyme before "aging" occurs. * **DFP (Diisopropyl fluorophosphate - Option D):** This is a potent, irreversible organophosphate compound used in research. Like malathion, it phosphorylates the enzyme, making it a target for pralidoxime. **NEET-PG High-Yield Pearls:** 1. **The "Aging" Phenomenon:** Oximes must be administered early (within 24–48 hours). Once the enzyme-phosphate bond "ages" (loses an alkyl group), it becomes chemically impossible for oximes to reactivate the enzyme. 2. **Carbamate Exception:** While oximes are generally avoided in carbamate poisoning (like Neostigmine or Physostigmine), **Pralidoxime is specifically contraindicated in Carbaryl poisoning** as it significantly increases toxicity. 3. **Atropine vs. Oxime:** Atropine treats the *symptoms* (muscarinic blocker), while Oximes treat the *cause* (enzyme reactivator). Atropine has no effect on skeletal muscle paralysis; only oximes can reverse nicotinic effects.
Explanation: **Explanation:** In Organophosphorus (OP) poisoning, the primary goal of atropinization is to counteract the life-threatening "killer B’s": **Bradycardia** and **Bronchorrhea** (excessive bronchial secretions). **Why Heart Rate is the Best Indicator:** Atropine is a competitive muscarinic antagonist. In OP poisoning, the excess acetylcholine causes severe bradycardia and hypotension. An increase in **heart rate (>80-100 bpm)** is considered the most reliable clinical endpoint for successful atropinization because it directly reflects the reversal of vagal overstimulation and indicates that the systemic muscarinic blockade is effective. Along with the clearing of bronchial secretions, heart rate serves as the primary guide for adjusting the dose. **Why Other Options are Incorrect:** * **B. Pupil:** While mydriasis (dilation) occurs with atropine, it is a **poor indicator**. Pupils may remain constricted due to local ocular exposure or may dilate before systemic toxicity is fully reversed. * **C. Blood Pressure:** BP is influenced by multiple factors, including nicotinic effects of OP poisoning and fluid status, making it less specific than heart rate. * **D. Ventilation:** While atropine helps by reducing secretions and bronchospasm, ventilation is also dependent on nicotinic effects at the neuromuscular junction (muscle paralysis), which atropine **does not** reverse. **Clinical Pearls for NEET-PG:** * **Signs of Atropinization:** Tachycardia (HR >100), clear breath sounds (no rales), and dry axilla. * **Pralidoxime (PAM):** Acts as a cholinesterase regenerator; it works on both muscarinic and nicotinic receptors but must be given before "aging" of the enzyme occurs. * **Atropine Overdose:** Remember the mnemonic "Mad as a hatter, Red as a beet, Dry as a bone, Blind as a bat, Hot as a hare."
Explanation: **Explanation:** **Correct Option: A (ACE Inhibitors)** ACE inhibitors (e.g., Enalapril, Lisinopril) cause hyperkalemia by inhibiting the Renin-Angiotensin-Aldosterone System (RAAS). By blocking the conversion of Angiotensin I to Angiotensin II, they reduce the secretion of **Aldosterone** from the adrenal cortex. Since aldosterone is responsible for sodium reabsorption and potassium excretion in the distal tubules, its deficiency leads to potassium retention. **Incorrect Options:** * **B. Chlorthalidone:** This is a thiazide-like diuretic. It increases sodium delivery to the distal tubule, promoting potassium excretion, which leads to **hypokalemia**. * **C. Amphotericin B:** This antifungal is notorious for nephrotoxicity. It causes distal renal tubular acidosis (Type 1 RTA) and increases membrane permeability, leading to significant wasting of potassium and magnesium (**hypokalemia**). * **D. Amiodarone:** While it has many side effects (thyroid dysfunction, pulmonary fibrosis), it does not typically affect serum potassium levels. However, hypokalemia should be corrected before starting Amiodarone to prevent Torsades de Pointes. **High-Yield Clinical Pearls for NEET-PG:** * **Mnemonic for Hyperkalemia (K-BANK):** **K**-sparing diuretics (Spironolactone), **B**eta-blockers, **A**CE inhibitors/ARBs, **N**SAIDs, and **K**-supplementation. * **ECG in Hyperkalemia:** Tall peaked T-waves (earliest sign), PR prolongation, and widened QRS (sine wave pattern). * **Drug Interaction:** Combining ACE inhibitors with Spironolactone or NSAIDs significantly increases the risk of life-threatening hyperkalemia.
Principles of Clinical Pharmacology
Practice Questions
Therapeutic Drug Monitoring
Practice Questions
Drug Toxicity and Overdose
Practice Questions
Antidotes and Their Applications
Practice Questions
Management of Drug Poisoning
Practice Questions
Drug-Induced Liver Injury
Practice Questions
Drug-Induced Kidney Injury
Practice Questions
Drug-Induced Blood Dyscrasias
Practice Questions
Drug-Induced QT Prolongation
Practice Questions
Pharmacovigilance
Practice Questions
Get full access to all questions, explanations, and performance tracking.
Start For Free